SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51728The CEO said they don't have pre-determined measures to meet regarding hazarA.J. Mullen-4/8/2021
51727Agree. I should have distinguished between the market for NDD and DD. But FGENArt Bechhoefer-4/8/2021
51726Oral drug over needles is always the patients preference so I still see value ifDewDiligence_on_SI-4/8/2021
51725How difficult will approval be? I assume that's why the price keeps fallingConundrum-4/8/2021
51724Oxford Nanopore IPO is apparently on the way in the second half of this year. Ponigel bates-4/8/2021
51723FDA approves first test of CRISPR to correct genetic defect causing sickle cell Frank Sully-4/8/2021
51722EPO isn't being used much in NDD. So Roxa wasn't going to replace, they JamesK-4/7/2021
51721More likely it would taken longer to replace epo type drugs, but they would evenArt Bechhoefer-4/7/2021
51720If the FDA sees Roxa as no safer than EPO that would put the large NDD market inJamesK-4/7/2021
51719I listened to a replay of the cc, having been unable to join the call yesterday.Art Bechhoefer-4/7/2021
51718No, the CEO didn't say anything so inflammatory. That would have been addinA.J. Mullen-4/7/2021
51717Does the statement of the CEO suggest that the former chief medical officer, whoArt Bechhoefer24/7/2021
51716The data were from FGEN, analyzed by FGEN whose CEO was careful to say the mistaA.J. Mullen-4/7/2021
51715Haven't accessed the replay yet, but will do so tomorrow. I notice that AKBArt Bechhoefer-4/6/2021
51714I got on the call without an issue, but the hosting company had a problem. AnalA.J. Mullen-4/6/2021
51713Akebia also submitted its NDA for vadadustat today. Vadadustat could get approvArt Bechhoefer-4/6/2021
51712Good call, worth listening to the recorded version. They say they can no longerA.J. Mullen14/6/2021
51711That's additional information I would have preferred sooner. It seems like A.J. Mullen-4/6/2021
51710What's the significance of the latest news on roxadustat, which has resultedArt Bechhoefer-4/6/2021
51709Invitae gets $1.2B cash investment from Softbank and acquires Genosity, a genomA.J. Mullen-4/5/2021
51708The FTC is seeking to stop the next Illumina proposed merger, wsj.com. The voteA.J. Mullen-3/31/2021
51707I miswrote. NTLA is going after ATTR, an indication for which ALNY has a drug aA.J. Mullen-3/29/2021
51706IONS had a PR this morning: finance.yahoo.comDewDiligence_on_SI-3/29/2021
51705The article in The Economist, which mentioned Ionis Pharmaceuticals and its antiArt Bechhoefer13/29/2021
51704DD -- Thanks for providing that list of recent IPO's, which, taken together Art Bechhoefer23/29/2021
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News